[en] Inflammatory bowel diseases (IBD) are characterized by a sustained inflammatory cascade that gives rise to the release of mediators capable of degrading and modifying bowel wall structure. Our aims were (i) to measure the production of matrix metalloproteinase-3 (MMP-3), and its tissue inhibitor, tissue inhibitor of metalloproteinase-1 (TIMP-1), by inflamed and uninflamed colonic mucosa in IBD, and (ii) to correlate their production with that of proinflammatory cytokines and the anti-inflammatory cytokine, IL-10. Thirty-eight patients with IBD, including 25 with Crohn's disease and 13 with ulcerative colitis, were included. Ten controls were also studied. Biopsies were taken from inflamed and uninflamed regions and inflammation was graded both macroscopically and histologically. Organ cultures were performed for 18 h. Tumour necrosis factor-alpha (TNF-alpha), IL-6, IL-1beta, IL-10, MMP-3 and TIMP-1 concentrations were measured using specific immunoassays. The production of both MMP-3 and the TIMP-1 were either undetectable or below the sensitivity of our immunoassay in the vast majority of uninflamed samples either from controls or from those with Crohn's disease or ulcerative colitis. In inflamed mucosa, the production of these mediators increased significantly both in Crohn's disease (P < 0.01 and 0.001, respectively) and ulcerative colitis (P < 0.001 and 0.001, respectively). Mediator production in both cases was significantly correlated with the production of proinflammatory cytokines and IL-10, as well as with the degree of macroscopic and microscopic inflammation. Inflamed mucosa of both Crohn's disease and ulcerative colitis show increased production of both MMP-3 and its tissue inhibitor, which correlates very well with production of IL-1beta, IL-6, TNF-alpha and IL-10.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Ribbens, Clio ; Centre Hospitalier Universitaire de Liège - CHU > Rhumatologie
1 Desreumaux P, Brandt E, Gambiez L et al. Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. Gastroenterology 1997; 113:118-26.
2 Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C, Strober W. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. J Immunol 1996; 157:1261-70.
3 Reimund JM, Wittersheim C, Dumont S, Muller CD, Kennet JS, Baumann R, Poindron P, Duclos B. Increased production of tumor necrosis factor-α, interleukin-1β. and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996; 39:684-9.
4 Reinecker H-C, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, Raedler A. Enhanced secretion of tumour necrosis factor-alpha, IL-6 and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94:174-81.
5 Stevens C, Wlaz G, Singaram C et al. Tumor necrosis factor-α, interleukin-1β, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992; 37:818-26.
6 Nielsen OH, Koppen T, Rüdiger N, Horn T, Eriksen J, Kirman I. Involvement of interleukin-4 and -10 in inflammatory bowel disease. Dig Dis Sci 1996; 41:1786-93.
7 Schmit A, Van Gossum A, Carol M, Mascart-Lemone F. Different cytokine patterns within inflamed and non inflamed colonic mucosa in Crohn's disease. Gastroenterology 1998; 114:G4417(Abstr.).
8 Kucharzik T, Stoll R, Lügering N, Domschke W. Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 100:452-6.
9 Schreiber S, Heinig T, Thiele HG, Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995; 108:1434-44.
10 Kusano K, Miyaura C, Inada M, Tamura T, Ito A, Nagase H, Kamoi K, Suda T. Regulation of matrix metalloproteinases (MMP-2-3-9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology 1998; 139:1338-45.
11 Saren P, Welgus HG, Kovanen PT. TNF-α and IL-1β selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol 1996; 157:4159-65.
12 Murphy G, Reynolds JJ, Werb Z. Biosynthesis of tissue inhibitor of metalloproteinases by human fibroblasts in culture. Stimulation by 12-o-tetradecanoylphorbol 13-acetate and interleukin 1 in parallel with collagenase. J Biol Chem 1985; 260:3079-83.
13 Lotz M, Guerne P-A. Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity (TIMP-1/EPA). J Biol Chem 1991; 266:2017-20.
14 Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer J-M. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 1995; 96:2304-10.
15 Pender SLF, Breese EJ, Günther U, Howie D, Wathen NC, Schuppan D, McDonald TT. Suppression of cell-mediated injury in human gut by interleukin 10: role of matrix metalloproteinases. Gastroenterology 1998; 115:573-83.
16 Reitamo S, Remitz A, Tamai K, Uitto J. Interleukin-10 modulates type 1 collagen and matrix metalloproteinase gene expression in cultured human skin fibroblasts. J Clin Invest 1994; 94:2489-92.
17 Stetler-Stevenson W. Type IV collagenase in tumour invasion and metastasis. Cancer Metastasis Rev 1990; 9:289-303.
18 Bailey CJ, Hembry RM, Alexander A, Irving MH, Grant ME, Shuttleworth CA. Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine. J Clin Pathol 1994; 47:113-6.
19 Saarialho-Kere UK, Vaalmo M, Puolakkainen P, Airola K, Parks WC, Karjalainen-Lindsberg M-L. Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J Pathol 1996; 148:519-26.
20 Pender SLF, Tickle SP, Docherty AJP, Howie D, Wathen NC, McDonald TT. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 1997; 158:1582-90.
21 Pender SLF, Fell JME, Chamow SM, Ashkenazi A, McDonald TT. A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol 1998; 160:4098-103.
22 Albin RJ, Senior RM, Welgus HG, Connoly NL, Campbell EJ. Human alveolar macrophages release an inhibitor of metalloproteinase elastase in vitro. Am Rev Respir Dis 1987; 135:1281-5.
23 Howard EW, Bullen EC, Banda MJ. Regulation of the autoactivation of human 72-kDa progelatinase by tissue inhibitor of metalloproteinase-2. J Biol Chem 1991; 266:13064-9.
24 Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's disease activity index (CDAI). Gastroenterology 1979; 77:843-6.
25 Wardle TD, Hall L, Turnberg LA. Use of coculture of colonic biopsies to investigate the release of eicosanoids by inflamed and uninflamed mucosa from patients with inflammatory bowel disease. Gut 1992; 33:1644-51.
26 Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean ? Gut 1991; 32:174-8.
27 Autsbach F, Braunstein J, Helmke B et al. In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am J Pathol 1998; 153:121-30.
28 Ito A, Ito Y, Sasaguri Y, Norimatsu M, Mori Y. Effects of interleukin6 on the metabolism of connective tissue components in rheumatoid synovial fibroblasts. Arthritis Rheum 1992; 35:1197-201.
29 Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, Lobo AJ, Taylor CJ, Evans GS. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999; 117:814-22.